

IN THE CLAIMS:

Please enter the attached listing of claims into the application. This listing of claims replaces all prior listing of claims in the application.

LISTING OF CLAIMS

1-32. (Cancelled)

33. (Currently Amended) An isolated human or humanized monoclonal antibody (Mab), fragment antibody (Fab) or single chain fragment (scFv) antibody having the binding specificity of the IK17 antibody;

wherein the human or humanized monoclonal antibody (Mab), fragment antibody (Fab) or single chain fragment (scFv) antibody comprises [[a]] the variable light chain encoded by the nucleotide sequence of SEQ ID NO:1 and [[a]] the variable heavy chain encoded by the nucleotide sequence of SEQ ID NO:2;

wherein the human or humanized monoclonal antibody, fragment antibody (Fab) or single chain fragment (scFv) is specific for oxidation specific epitopes found on copper-induced oxidized low density lipoprotein (Cu-OxLDL) or malondialdehyde low density lipoprotein (MDA-LDL);

wherein the human or humanized monoclonal antibody, fragment antibody (Fab) or single chain fragment (scFv) does not bind to native LDL;

wherein the human or humanized monoclonal antibody, fragment antibody (Fab) or single chain fragment (scFv) inhibits uptake of CuOxLDL by macrophages; and

wherein the human or humanized monoclonal antibody, fragment antibody (Fab) or single chain fragment (scFv) binds the epitope in vivo at a detectably higher rate than the rate of binding to normal vasculature.

34. (Previously Presented) The isolated human or humanized monoclonal antibody (Mab), fragment antibody (Fab) or single chain fragment (scFv) antibody according to claim 33, wherein the antibody is a monoclonal antibody.

35. (Currently Amended) The isolated human or humanized monoclonal antibody (Mab), fragment antibody (Fab) or single chain fragment (scFv) antibody according to claim 33, wherein the antibody is a fragment antibody (Fab).

36. (Currently Amended) The isolated human or humanized monoclonal antibody (Mab), fragment antibody (Fab) or single chain fragment (scFv) antibody according to claim 33, wherein the antibody is a single chain fragment (scFv).

37. (Previously Presented) The isolated human or humanized monoclonal antibody (Mab), fragment antibody (Fab) or single chain fragment (scFv) antibody according to claim 33, wherein the antibody is human.

38. (Previously Presented) The isolated human or humanized monoclonal antibody (Mab), fragment antibody (Fab) or single chain fragment (scFv) antibody according to claim 33, wherein the antibody is humanized.

39. (Previously Presented) The isolated human or humanized monoclonal antibody (Mab), fragment antibody (Fab) or single chain fragment (scFv) antibody according to claim 33, wherein the antibody is detectably labeled.

40. (Previously Presented) The isolated human or humanized monoclonal antibody (Mab), fragment antibody (Fab) or single chain fragment (scFv) antibody according to claim 33 further comprising a therapeutic agent covalently linked to the antibody.